Share on StockTwits

InterMune (NASDAQ:ITMN) was downgraded by stock analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a report issued on Tuesday, reports.

A number of other firms have also recently commented on ITMN. Analysts at JPMorgan Chase & Co. downgraded shares of InterMune from an “overweight” rating to a “neutral” rating in a research note on Tuesday. Separately, analysts at Jefferies Group upgraded shares of InterMune from an “underperform” rating to a “hold” rating in a research note on Monday. They now have a $74.00 price target on the stock, up previously from $25.00. Finally, analysts at William Blair raised their price target on shares of InterMune from $55.00 to $74.00 in a research note on Monday. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $56.30.

In other InterMune news, EVP Paul D. Arata unloaded 7,500 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $50.00, for a total value of $375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of InterMune (NASDAQ:ITMN) opened at 72.85 on Tuesday. InterMune has a 52-week low of $10.95 and a 52-week high of $73.18. The stock has a 50-day moving average of $46.61 and a 200-day moving average of $36.93. The company’s market cap is $7.866 billion. InterMune also was the target of unusually large options trading on Monday. Stock investors acquired 5,253 call options on the stock. This represents an increase of 156% compared to the typical volume of 2,052 call options.

InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The company’s quarterly revenue was up 141.2% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.75 earnings per share for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

The Fly On The Wall

Receive News & Ratings for InterMune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterMune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.